Home | Links | Contact Us | More About Intellectual Property | Bookmark
Search patents:
Home Drugs Human-immunodeficiency-virus-decoy

 Method for generating and identifying antibodies directed against a B7
Accordingly, the present invention identifies the B7 antigen as a ligand recognized by the CD28 ...


 Polypeptide that interacts with heat shock proteins
Described herein are the isolation and characterization of a polypeptide, particularly a ...


 1,2-Biguanides
What is claimed is: 1. A substituted biguanide of the formula ##EQU8## wherein R.sub.1 is alkyl of 1...


 Biguanide salts
OF THE INVENTION The invention relates to biguanide salts. In another aspect, the invention ...


 Inhibitors of dipeptidyl-aminopeptidase type IV
What is claimed is: 1. A method for treating transplant rejection in a patient comprising ...


 Process for preparing anti-obesity protein
OF THE INVENTION For purposes of the present invention, as disclosed and claimed herein, the ...


 Use of GLP-1 or analogs to abolish catabolic changes after surgery
The present invention therefore presents for the first time a method of attenuating post-surgical ...


 Effects of sporoderm-broken germination activated ganoderma spores on treatment of spinal cord injury
OF THE INVENTION The present invention provides a method for effective treatment of spinal cord ...


 Leptospira rare outer membrane proteins
The present invention presents two novel leptospiral membrane proteins: LipL1 and LipL2. In ...


 Interleukin-1 beta converting enzyme like apoptotic protease-6
Toward these ends, and others, it is an object of the present invention to provide polypeptides, ...


 Human immunodeficiency virus decoy

Details
Inventors: Kossovsky, Nir; Gelman, Andrew E.; Sponsler, Edward E.;
Assignee: The Regents of the University of California (Oakland, CA)
Primary Examiner: Page; Thurman K.
Assistant Examiner: Spear; James M.
Attorney, Agent or Firm: Poms, Smith, Lande & Rose

A biologically active composition made up of core particles having diameters of less than about 1000 nanometers which are coated with a layer which is designed to allow attachment of biologically active proteins, peptides or pharmacological agents to the microparticles. When Human Immunodeficiency Virus (HIV) viral protein is attached to the core particles, the result is a viral decoy which accurately mimics native HIV in size, structure and surface character while being entirely devoid of virulent activity due to the microparticle core. The HIV decoy is useful as a vaccine for treating mammals to elicit an immune response.

DETAILED DESCRIPTION OF THE INVENTION The present invention has wide application to immunologic procedures and methods wherein antigenic material or other biologically active moieties are utilized.
These areas of application include vaccination agents, antigen agents used to raise antibodies for subsequent diagnostic uses and antigenic compounds used as diagnostic tools.
The composition of the invention can also be used in a wide variety of other applications where there is a need to anchor a protein, peptide or pharmacological agent to a core particle in order to preserve and/or enhance bioreactivity.
The compositions of the present invention include nanocrystalline core particles (diameters of less than 1000 nm) which are coated with a surface energy modifying layer that promotes bonding of proteins, peptides or pharmaceutical agents to the particles.
The coating modifies the surface energy of the nanocrystalline core particles so that a wide variety of immunogenic proteins, peptides and pharmaceutical agents may be attached to the core particle without significant loss of antigenic activity or denaturization.
The result is a biologically active composition which includes a biologically inert core.
The end use for the compositions of the present invention will depend upon the particular protein, peptide or pharmacological agent which is attached to the coated core particle.
For example, proteins or peptides having antigenic activity may be attached to provide compositions useful as immunodiagnostic tools.
Viral fragments or protein coatings having immunogenic activity may be attached to provide a vaccine.
Also, pharmacological agents may be attached to provide compositions which are useful in treating diseases.
For preparing decoy viruses for use as vaccines, particles having diameters of between about 10 to 200 nanometers are preferred since particles within this size range more closely mimic the diameter of DNA and RNA cores typically found in viruses.
The core particles may be made from a wide variety of inorganic materials including metals or ceramics



Related patents
  Capsid forming and cystein modified chimaeric MS2-coat protein
We claim: 1. A modified coat protein capable of forming a capsid which comprises the coat protein of a bacteriophage selected from the group consisting of MS-2, R17 and ...
  Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
This invention relates to the discovery of an anti-idiotype antibody that is capable of recruiting a tumor-specific response against GD2. The antibody is designated 1A7....
  Strategically modified hepatitis B core proteins and their derivatives
The present invention relates to a strategically modified hepatitis B core (HBc) protein that is linked to a pendent hapten through chemically-reactive amino acid ...
  Chimeric biotin-binding papillomavirus protein
OF THE INVENTION The first domain of the chimeric protein includes at least a portion of a papillomavirus L1 or L2 protein. The sequence of the L1 and L2 proteins of ...
  Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
OF THE INVENTION DEFINITIONS As used in this application, the following words or phrases have the meanings specified. As used herein, a "bispecific fusion protein" ...
  MYPPPY variants of CTL A4 and uses thereof
OF THE INVENTION Definition As used in this application, the following words or phrases have the meanings specified. As used herein "blocking B7 interaction" means to ...
  CTLA4 receptor and uses thereof
OF THE INVENTION DEFINITION As used in this application, the following words or phrases have the meanings specified. As used herein "blocking B7 interaction" means to ...
  CTLA4/CD28Ig hybrid fusion proteins and uses thereof
OF THE INVENTION DEFINITION As used in this application, the following words or phrases have the meanings specified. As used herein "blocking B7 interaction" means to ...
  Method of regulating cellular processes mediated by B7 and CD28
Accordingly, the present invention identifies the B7 antigen as a ligand recognized by the CD28 receptor. The B7 antigen, or its fragments or derivatives are reacted ...
  Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
This invention is based, at least in part, on the discovery of novel ligands which bind a T cell surface molecule and induce antigen specific apoptosis in an activated T ...

0.284

Archive: All patents - Links

Copyright (c)2006 Eipa-patents.org - All rights reserved